These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 18625449)

  • 1. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
    Bateman RJ; Klunk WE
    Neurotherapeutics; 2008 Jul; 5(3):381-90. PubMed ID: 18625449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H; Zadeh EH; Khan RH
    Int J Biol Macromol; 2021 Jan; 167():382-394. PubMed ID: 33278431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the cause of sporadic Alzheimer's disease.
    Zetterberg H; Mattsson N
    Expert Rev Neurother; 2014 Jun; 14(6):621-30. PubMed ID: 24852227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
    Padilla-Zambrano HS; García-Ballestas E; Quiñones-Ossa GA; Sibaja-Perez AE; Agrawal A; Moscote-Salazar LR; Menéndez-González M
    Curr Alzheimer Res; 2020; 17(9):781-789. PubMed ID: 33280597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Review on Alzheimer's Disease: Causes and Treatment.
    Breijyeh Z; Karaman R
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33302541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.
    Adalbert R; Gilley J; Coleman MP
    Trends Mol Med; 2007 Apr; 13(4):135-42. PubMed ID: 17344096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium signaling in Alzheimer's disease & therapies.
    Tong BC; Wu AJ; Li M; Cheung KH
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1745-1760. PubMed ID: 30059692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau therapeutics for Alzheimer's disease: the promise and the challenges.
    Gold M
    J Mol Neurosci; 2002 Dec; 19(3):331-4. PubMed ID: 12540060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease.
    Narayanan SE; Sekhar N; Rajamma RG; Marathakam A; Al Mamun A; Uddin MS; Mathew B
    Curr Protein Pept Sci; 2020; 21(12):1164-1173. PubMed ID: 32957903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPK: Potential Therapeutic Target for Alzheimer's Disease.
    Yang L; Jiang Y; Shi L; Zhong D; Li Y; Li J; Jin R
    Curr Protein Pept Sci; 2020; 21(1):66-77. PubMed ID: 31424367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β and Tau at the Crossroads of Alzheimer's Disease.
    Gallardo G; Holtzman DM
    Adv Exp Med Biol; 2019; 1184():187-203. PubMed ID: 32096039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
    Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
    Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.